Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00492 (
hypoxanthine-guanine phosphoribosyltransferase
)
2,385
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
N3-o-toluyl-fluorouracil (TFu) was a potent water-insoluble prodrug of 5-fuorouracil (5-Fu). To improve the solubility of TFu, TFu loaded nanosuspension (TFu-LNS) was prepared by high-pressure homogenization method. The results of in vitro release studies showed that 5-Fu was sustained released from TFu-
LNS
. Then in vitro antitumor activity of TFu-
LNS
in terms of antiproliferative activity, induction of apoptosis and G1 cycle arrest on human breast adenocarcinoma cell line (MCF-7) and human gastric carcinoma cell line (BGC) was evaluated. The results of MTT assay showed that TFu-
LNS
exhibited higher antiproliferative activity against MCF-7 and BGC cells than TFu DMSO-water solution and 5-Fu solution. The apoptosis induced by TFu-
LNS
was assessed by Annexin V-FITC/PI double staining and Tunnel assay. And the results of two methods both clearly indicated that the superiority of TFu-
LNS
to TFu DMSO-water solution and 5-Fu solution in increasing the apoptosis rate of MCF-7 and BGC cells. The results of flow cytometric (FCM) analysis demonstrated that TFu-
LNS
could induce G1 cycle arrest of MCF-7 and BGC cells. Furthermore, in vivo pharmacokinetics study in Wistar rats indicated that TFu-
LNS
was capable of increasing the parameters of AUC(0-infinity) and
MRT
significantly by sustained releasing 5-Fu. Therefore, the overall results suggested that the TFu-
LNS
could enhance anti-tumor effect and hold great potential to be developed for cancer treatments.
...
PMID:The in vitro anti-tumor efficacy and the pharmacokinetics of N3-o-toluyl-fluorouracil loaded nanosuspension (TFu-LNS). 2380 9